Medical Device

What it is

Medical device — definition means any instrument, apparatus, appliance, software, implant, reagent, material, or other article intended by the manufacturer to be used—alone or in combination—for a specific medical purpose such as diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease or injury; investigation, replacement, or modification of anatomy or a physiological process; or control of conception. It does not achieve its primary intended action by pharmacological, immunological, or metabolic means, although such means may assist it (EU: MDR 2017/745 Art. 2(1); US: FD&C Act §201(h), 21 U.S.C. 321(h)).

Regulatory framework

• EU (MDR): Legal definition and scope (MDR Art. 2(1)); classification rules (MDR Annex VIII); General Safety and Performance Requirements (MDR Annex I); technical documentation (Annex II–III); conformity assessment/CE marking (Annex IX–XI).
• US (FDA): Statutory definition (FD&C Act §201(h)); device classification (21 CFR 860); pathways: 510(k) (21 CFR 807 Subpart E), De Novo (21 CFR 860 Subpart D), PMA (21 CFR 814); labeling/UDI (21 CFR 801, 830); QMSR/Part 820.
• Software: EU Rule 11 for stand-alone software (MDR Annex VIII Rule 11); US software devices regulated per intended use and risk; general wellness products fall outside device scope if they make only low-risk wellness claims.

Scope & inclusions

• Forms: Instruments, machines, implants, disposables, accessories, and software as a medical device (SaMD).
• Use contexts: Professional healthcare, home use, point-of-care, and connected/remote environments.
• Typical exclusions: Products whose primary intended action is pharmacological, immunological, or metabolic (medicinal products), and general consumer wellness items with no medical purpose.

Process — lifecycle at a glance

• 1) Intended purpose & classification: Define purpose, indications, users, and environments; then assign risk class using MDR Annex VIII or 21 CFR 860.
• 2) QMS & design controls: Build an ISO 13485-aligned QMS; apply design/production controls (EU Annex I; US 21 CFR 820).
• 3) Technical documentation: Compile evidence on safety, performance, risk, usability, and labeling (EU Annex II–III; US submission dossier).
• 4) Conformity/market access: Undergo NB assessment and CE marking (EU Annex IX–XI) or submit 510(k)/De Novo/PMA in the US.
• 5) Post-market: Run PMS, vigilance/recalls, and CAPA; maintain UDI/registration and keep files current (MDR Chapter VII; 21 CFR 803/806).

Borderline & combination notes

• Combination products: If a device incorporates a medicinal substance, or is integral to a medicine, apply the framework driven by the principal intended action (EU: MDR Art. 1(8)–(9)/Art. 117; US: PMOA via 21 CFR Part 3).
• Accessories: Items that enable a device to be used per its purpose are regulated in their own right (MDR Art. 2; US follows intended use).
• Wellness vs medical: Claims to diagnose, treat, or mitigate disease bring a product into device scope; purely general wellness claims do not.

Common pitfalls

• Vague intended purpose that blurs indications, users, or environments, which then misguides class and evidence.
• Marketing statements that extend beyond the cleared/CE-marked scope.
• Assuming software is exempt; stand-alone software often falls under Rule 11 (EU) and device controls (US).
• Misclassifying borderline drug–device combinations and skipping required consultations or opinions.

Quick checks

• Does the stated purpose avoid pharmacological, immunological, or metabolic primary action?
• Are condition, population, user, and setting explicit and testable?
• Is the risk class justified against MDR Annex VIII or 21 CFR 860, including software rules?
• Do labeling, claims, and evidence align across technical files and submissions?